C-X-C motif chemokine 9 Antibodies

C-X-C motif chemokine 9 (CXCL9)

Cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory reaction. Chemotactic for triggered T-cells.

Binds to CXCR3. .

Gene Information

Human
Gene Name:	CXCL9
Uniprot:	Q07325
Entrez:	4283

Family

Belongs to:
intercrine alpha (chemokine CxC) family

Alternative Names

chemokine (C-X-C motif) ligand 9; CMK; crg-10; C-X-C motif chemokine 9; CXCL9; Gamma-interferon-induced monokine; Humig; MIG; MIGSmall-inducible cytokine B9; monokine induced by gamma interferon; SCYB9Monokine induced by interferon-gamma

Molecular Weight

Mass (kDA):
14.019 kDA

Genomic Context

Human
Location:	4q21.1
Sequence:	4; NC_000004.12 (76001275..76007509, complement)

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Neoplasms
• Malignant Neoplasms
• Autoimmune Reaction
• Virus Diseases
• Tissue Adhesions
• Nervousness
• Infective Disorder
• Hepatitis
• Cholangiocarcinoma
• Carcinoma
• Autoimmune Diseases

• Inflammatory Response
• Fibrosis
• Arthritis
• Sclerosis
• Tumor Angiogenesis
• Hiv Infections
• Tuberculosis

Interacting Proteins

• CCDC155
• CCL21
• CCL26
• CCL5
• CXCL10

• CXCL12
• CXCL14
• DPP4
• PF4
• PPBP

• PTPN5
• SFTPC
• SYNE4

Pathways

• Pathogenesis
• Immune Response
• Secretion
• Chemotaxis
• Inflammatory Response
• Chemokine Production
• Angiogenesis
• Cell Migration
• Localization
• Cytokine Production
• Cell Activation
• Hypersensitivity
• Innate Immune Response

• Cell Proliferation
• T Cell Activation
• Cell Adhesion
• Cell Death
• T Cell Migration
• Viral Replication
• Chemokine Secretion

PTMs

• Phosphorylation
• Cleavage
• Methylation
• Demethylation

• Biotinylation
• Acetylation
• Dephosphorylation
• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CXCL9

Boster Bio - Best Uses Of The CXCL9 Marker

The Anti-MIG/CXCL9 marker is an important protein that is part of the immune system. We'll explore the clinical uses and advantages of this marker in this article. We'll also talk about the recent Campaign ASHASPHO Choosing wisely and how this molecule could be used in research or development. And finally, we'll explore the future of this protein.

Anti-MIG/CXCL9 marker

Boster Bio's Anti-MIG/CXCL9 antibody monoclonal and reacts with mouse CXCL9. This chemokine is part of the CXC chemokine family and is expressed on a variety of cells such as macrophages and monocytes along with endothelial cells and primary glial cells. Antibodies to this protein have been shown to increase the production of chemokines, integrin activation, cytoskeletal changes, and chemotactic migration.

The MIG and IP-10 molecules contribute to type 1 immune responses in the lung. MIG is inducible through the action IFN-g. This protein stimulates the production IP-10, an immune cell cytokine. The immune system is ineffective to respond to Klebsiella pneumoniae inhalation. The intrapulmonary infection of the bacteria triggers MIG mRNA, and IP-10 expression of mRNA.

The CXCL9 chemokine is able to bind to a network of cortical stroma cells and increase TCM peripheralization. It was also demonstrated that intranodal TCM distribution is correlated with CXCL9 immunoreactivity. These results are encouraging. These results suggest that the Anti–MIG/CXCL9 markers from Boster Bio could be helpful for guiding intranodal TCM peripherization.

Boster scientists can submit results for specific samples and species or for specific applications. This credit program for products is open to all scientists around the world. However it is crucial to remember that the procedure requires a few steps and careful documentation. Boster scientists can submit their findings in order to earn credit for their work and then receive credits for their product. Because of this, they must be confident in the data they supply. The advantages of this product are clear.

In the development of murine cerebral malaria for the development of murine cerebral malaria, the CXCR3 receptor on CD8+ T cells is crucial. This chemokine is essential for the recruitment of T cells to the brain. Therefore, mice lacking CXCR3 showed no significant effect on atherosclerosis when the gene was deleted. Infected with P. Berghei ANKA, mice without Mig were protected in part from cerebral malaria mortality.

Benefits

The CXCL9 marker, referred to as the C-X-C motif-based chemokine ligand 9, is an immune-checkpoint molecule required for the initiation of antitumour response. Researchers have recently tried to discover if CXCL9 expression is associated with breast cancer immune-cell activity and the number. They used open-source databases and online tools to investigate the expression of CXCL9 in cancer cells. Immunohistochemistry experiments were conducted to confirm their findings. The expression of CXCL9 mRNA in breast cancers was significantly higher than that in normal tissues. This was associated with higher survival in patients with ER-negative tumors.

In a murine orthotopic model of PAAD, CXCL9 increased the weight of tumors by over 5percent and increased the speed of tumour growth. Furthermore, immunohistological studies revealed that CXCL9 treatment significantly reduced the amount of CD8+ T cells that are cytotoxic. The treatment had little influence on the pattern and activity of innate immune cells in the tumor microenvironment. This suggests that CXCL9 may play a crucial role in controlling the growth of tumors.

The CXCL9 marker can be used to predict the prognostic significance of patients. Kariminia and colleagues recently conducted research. found a larger area under the receiver operating characteristic curve than a single biomarker. However, a clear cutoff value has not yet been confirmed. It will be helpful to guide the clinical practice of a physician if more research is done on the CXCL9 marker.

Although research has been inconsistent, CXCL9 has been proven to increase survival rates for breast cancer patients. The TIMER database showed a significant correlation between CXCL9 and OS and DFS. Higher levels of CXCL9 were associated with improved overall survival and CS. These results suggest that CXCL9 expression is beneficial to many breast cancer patients. This could have implications for the development and treatment of cancer treatments.

Recent research has revealed that CXCL9 was highly predictive of infection. It also promoted B cells activity in antiinfective diseases. In addition, studies have found that CXCL9 could be detected in multiple-factor combination prediction studies. However, the specificity of the combined marker was just 68.5 percent however, which isn't enough to be used in clinical trials. The CXCL9 marker could be used to aid in earlier intervention and monitoring.

Clinical Applications

The clinical applications of CXCL9 are a fascinating new area of study in immunotherapy. CXCL9 is a kind of cytokine that is produced in response to a variety of stimuli, including interferon-g and TNF-a. This protein is involved in inflammatory intestinal disease. Its increased secretion during response could aid in the development immunotherapies.

In experimental asthma, CXCL9 can be used to activate TCF1+ T cells to specific niches within the tumor microenvironment. CXCL9 also has powerful angiostatic properties which inhibit the growth of tumors and also wound healing. This makes it an excellent target for immunotherapy in these conditions. However, further studies are required to determine if CXCL9 could also be used to attack cancerous cells.

It is interesting to note that it is interesting to note that the CXCL9 gene is responsible for activating monocyte chemotactic action. It is also an ligand for CXCR3 chemokines like IL-2. The immunotherapy research is focusing on CXCL9-related diseases. These studies are insufficient and do not address the significance of CXCR3 Chemokines in modulating the immune system.

The Human genome is home to the CXCL9 human gene. Although the receptor for CXCL9 is not identified, CXCL9 gene expression is very similar to that of non-malignant cells. CXCL9 can be released by inflammation cells, which could trigger immune responses or inflammation. The CXCL9-mediated inflammation response can increase as the cell's membrane becomes more swollen.

In addition to the CXCL9 gene MIG/CXCL10 IP-10/CXCL10 also has high expression in tumor cells. These two cytokines are associated with the development of a variety of cancers, and their levels in the blood are related to the progression of these diseases. A study conducted by Hsin et al. discovered that high CXCL9 expression was associated with cancer progression and treatment response in nasopharyngeal tumors.

CXCL9 Chemokine plays an essential role in the diagnosis of Q fever. Infections that trigger the production of CXCL9 chemicals increase the likelihood of developing the disease. The serum CXCL9 levels can differentiate between recent and chronic Q fever. It's not as specific as the IFN-g/IL-2 production assay however it has shown great precision in detecting chronic Q fever in blood.

ASH-ASPHO Choosing Wisely Campaign

The ASH-ASPHO choosing Wiseley campaign is an excellent example of a campaign that seeks to encourage the use of and informed decision-making through health information. This report details the methods employed by the Task Force to develop this initiative, as well as the results. The report was written by members of ASH and ASPHO. All authors contributed to this research. They have read and approved the paper. These results reflect their opinions and their experiences.

After analyzing the evidence the ASH-ASPHO Choosing Wiseley task force evaluated each of the 380 recommendations. The task force began with 50 relevant recommendations , and narrowed it down to five. They evaluated the effectiveness of each recommendation in preventing harm to patients, the evidence base, and the general cost and frequency. The task force also looked at how the recommendations would impact the safety of patients as well as the practice.

Five items were submitted by the Choosing Wiselely Campaign to the ABIM Foundation. They were subject to minor changes in language but endorsed the ABIM Foundation recommendations. The recommendations are summarized in Table 2, along with the key references that support them. For instance platelet transfusions is not recommended for children suffering from hypoproliferative or thrombocytopenia in the event that the child is scheduled for an operation that is invasive.

The ASH-ASPHO Working to Choose Wisely Task Force comprises 13 experts in the fields of hematology as well as pediatric oncology. The experts selected five items that are related to tests and one treatment-related procedure. A member of each society served as the co-chair of the task group. The members of the panel have experience in the field of pediatric malignancy, nonmalignant Hematology, and laboratory hematology. They also included a lead author for the prior ASH Choosing wisely the recommendations.